Form 4: Adaptive Bio CEO Sells Shares Under 10b5-1 Plan

Adaptive Biotechnologies CEO and Chairman Chad M. Robins sold 124,998 shares of common stock for a weighted average price of $18.44 per share under a pre-arranged trading plan.

Summary

• Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corp (ADPT), disposed of 124,998 shares of common stock.
• The transaction occurred on February 2, 2026, at a weighted average price of $18.44 per share.
• The shares were sold in multiple transactions with prices ranging from $18.16 to $18.88.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robins on August 11, 2025.
• Following this transaction, Mr. Robins directly beneficially owns 2,459,245 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns that it is based on new, adverse material information.

Negatives

• A key executive, Chad M. Robins, disposed of a significant number of shares (124,998), which could be perceived negatively by some investors, despite being pre-planned.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a Rule 10b5-1 trading plan, are common for executives to manage personal finances, diversify holdings, or for liquidity purposes. Such pre-arranged sales typically carry less negative signaling than unplanned, open-market sales, as they are not usually a reaction to new, adverse material information.

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider ownership, though the pre-planned nature of the sale lessens the potential for negative interpretation.

Key Dates

Recommendation

The sale by CEO Chad M. Robins was conducted under a Rule 10b5-1 trading plan, which indicates it was pre-scheduled for personal financial planning rather than being driven by new, material information about the company's prospects. Therefore, this transaction alone does not suggest a fundamental change in the company's outlook that would warrant a 'buy' or 'sell' recommendation, making 'hold' appropriate.

Keywords

ADPT, Adaptive Biotechnologies, Chad M. Robins, Insider Trading, Form 4, Stock Sale, CEO, Director, 10b5-1 Plan